SCHEMBL4843440

SCHEMBL4843440

COc1ccc2c(CCc3ccccc3)nnc(Cl)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 4/20 0.47
PDE4B Q07343 4/20 0.47
PDE4C Q08493 4/20 0.47
PDE4D Q08499 4/20 0.47
PPARG P37231 2/20 0.44
PLA2G2A P14555 1/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTR1A P08908 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADORA2B P29275 1/20 0.40
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
KDR P35968 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838839 0.88 ALDH1A1 (0.54) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL6586299 0.87 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DPPARG
SCHEMBL4841956 0.84 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL4842364 0.81 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4843309 0.81 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4124808 0.80 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL4125179 0.79 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL26690613 0.77 KDM4E (0.45) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL6588161 0.76 PDE4A (0.71) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL6587711 0.76 SHMT2 (0.54) PDE4APDE4BPDE4CPDE4DKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 PDE4A 1615/4885PDE4B 1845/4885PDE4C 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.